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Introduction
The ATP-dependent SWI/SNF chromatin remodeling enzymes
alter histone:DNA contacts on nucleosomes in a manner that
promotes interaction of regulatory factors with the chromatin
template (Becker and Horz, 2002; Narlikar et al., 2002;
Peterson, 2002). The mechanism appears to be an energy-
dependent combination of twisting of the DNA helix and
displacement of the helix relative to the histone octamer
surface (bulging). This is supported by data demonstrating that
SWI/SNF can facilitate the binding of a transcription factor in
a manner dependent upon the specific orientation of the factor
binding site therefore arguing against a simple twisting model
(Imbalzano et al., 1994). Regardless of the exact mechanism(s)
behind nucleosome remodeling by SWI/SNF enzymes, recent
reports indicate that the SWI/SNF enzymes contribute to a
diverse collection of cellular gene activation events. In
particular, some genes that are turned on in response to
developmental or environmental signals seem to show a
requirement for SWI/SNF enzymes and their chromatin
remodeling activities (Agalioti et al., 2000; Barker et al., 2001;
Chi et al., 2002; de la Serna et al., 2000; de la Serna et al.,
2001a; DiRenzo et al., 2000; Kowenz-Leutz and Leutz, 1999;
Lee et al., 1999; Lemon et al., 2001; Liu et al., 2002;
Mudhasani and Fontes, 2002; Pattenden et al., 2002; Pedersen
et al., 2001; Soutoglou and Talianidis, 2002; Wang and
Hankinson, 2002).
However, the requirement for SWI/SNF enzymes during
activation of new gene programs is not absolute; not every gene
turned on or up-regulated in response to environmental or
differentiation signals requires SWI/SNF enzymes (de la Serna
et al., 2000; de la Serna et al., 2001b; Kowenz-Leutz and Leutz,
1999; Roy et al., 2002). In addition, the requirement of genes
that are constitutively active during cell culture growth for
SWI/SNF enzymes is limited; a microarray analysis of tumor
cells lacking or expressing the BRG1 catalytic subunit of some
SWI/SNF enzymes identified only 80 genes activated more
than three-fold by the presence of BRG1 (Liu et al., 2001). In
a limited number of instances, SWI/SNF enzymes have been
implicated in gene repression. The microarray analysis
identified two genes that were repressed by the presence of
BRG1 (Liu et al., 2001). SWI/SNF components have also been
implicated in the transcriptional repression of the c-fos gene
(Murphy et al., 1999) and the cad gene (Pal et al., 2003), of
neuronal specific gene expression by the REST transcription
factor (Battaglioli et al., 2002) and of CD4 silencing during T
cell activation (Chi et al., 2002). Repression of cyclin gene
expression by BRG1 is essential for Rb-mediated cell cycle
arrest (Strobeck et al., 2000; Zhang et al., 2000), and BRG1
also facilitates repression of E2F-mediated transcription (Wang
et al., 2002). The mechanism(s) by which SWI/SNF enzymes
promote transcriptional repression has not been well defined,
though associated histone deacetylase and methyl transferase
5847
The SWI/SNF enzymes belong to a family of ATP-
dependent chromatin remodeling enzymes that have been
functionally implicated in gene regulation, development,
differentiation and oncogenesis. BRG1, the catalytic core
subunit of some of the SWI/SNF enzymes, can interact with
known tumor suppressor proteins and can act as a tumor
suppressor itself. We report that cells that inducibly
express ATPase-deficient versions of BRG1 increase in cell
volume, area of attachment and nuclear size upon
expression of the mutant BRG1 protein. Examination of
focal adhesions reveals qualitative changes in paxillin
distribution but no difference in the actin cytoskeletal
structure. Increases in cell size and shape correlate with
over-expression of two integrins and the urokinase-type
plasminogen activator receptor (uPAR), which is also
involved in cell adhesion and is often over-expressed in
metastatic cancer cells. These findings demonstrate that
gene expression pathways affected by chromatin
remodeling enzymes can regulate the physical dimensions
of mammalian cell morphology.
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activities are required in at least some cases (Battaglioli et al.,
2002; Pal et al., 2003; Zhang et al., 2000). How SWI/SNF
directly or indirectly represses each of these down-regulated
promoters remains to be determined.
A number of cancer cell lines have been shown to be missing
one or more SWI/SNF subunits (DeCristofaro et al., 2001;
DeCristofaro et al., 1999; Wong et al., 2000), and targeted
disruption of at least two SWI/SNF subunits predisposes mice
heterozygous for these genes to tumors (Bultman et al., 2000;
Guidi et al., 2001; Klochendler-Yeivin et al., 2000; Roberts et
al., 2000). The link between mis-regulation of SWI/SNF
subunits, changes in cellular gene expression patterns and
tumorigenesis is unclear. Changes in physical as well as
metabolic properties are hallmarks of cellular transformation.
We were therefore intrigued when we noted that cells
expressing ATPase-deficient BRG1 increased in size and
changed shape.
Early studies manipulating the surface attachment of
cultured cells demonstrated that cell shape could regulate
proliferation (Folkman and Moscona, 1978) and gene
expression (Ben-Ze’ev et al., 1980; Farmer et al., 1978). These
effects involve integrin binding to extracellular matrix (ECM)
molecules triggering signaling pathways, but integrin
occupancy by ECM is not sufficient (Chen et al., 1997; Huang
et al., 1998; Huang and Ingber, 1999). Topographies of ECM
that force cells into rounded or flattened shapes are also
important regulators of cell cycle progression and survival.
While cell shape can be experimentally manipulated by
specifying ECM geometry on growth surfaces, the normal
determinants of shape have been unknown. We show an
experimental system in which cell shape can be regulated by
manipulations of the chromatin remodeling machinery in
proliferating cells. Expression of mutant SWI/SNF chromatin
remodeling enzymes causes increases in area of cell attachment
and cell volume together with increases in levels of proteins
involved in cell signaling, cell adhesion and cancer metastasis.
Materials and Methods
Cell counts and mRNA and protein analyses
Properties of and growth conditions for cell lines expressing mutant
BRG1 and the tet-VP16 control cell lines have been described
previously (de la Serna et al., 2000). For experiments described here,
cells were passaged into media lacking or containing 2 µg/ml
tetracycline and assayed as indicated in the figure legends. For cell
counting experiments, cells were trypsinized, washed, counted using
a Coulter Counter, and plated in the presence or absence of
tetracycline at 50,000 cells per 100 mm dish. Whole cell extracts and
western blots were performed as described previously (de la Serna et
al., 2000) except for the urokinase-type plasminogen activator
receptor (uPAR) blot, for which a RIPA buffer was used to generate
extracts, and reducing agent was omitted from the extraction buffer
and the SDS gel-loading buffer. Antibodies used for westerns
included: α5 integrin and αV integrin (Chemicon; Temecula, CA),
rabbit antisera against mouse uPAR (Solberg et al., 2001), rabbit
antisera against β1 integrin (Heino et al., 1989), N-cadherin and β-
catenin (Zymed; South San Francisco, CA), focal adhesion kinase
(LabVision/Neomarkers, Inc.; Fremont, CA), paxillin (BD
Pharmingen; San Diego, CA), actin (clone C4; Valeant
Pharmaceuticals International, Costa Mesa, CA), and PI3K p85 N-
SH2 domain (Upstate; Charlottesville, VA).
Northern blotting was done as described previously (Yan et al.,
2002) using stringency washes performed with 0.1× SSC, 0.1% SDS
at 65°C. The blot was probed at 65°C with random-primed
radiolabeled cDNAs corresponding to nucleotides 80-997 of mouse
uPAR. Loading efficiencies were checked by reprobing the blot with
a random-prime radiolabeled mouse actin cDNA. The following
primer sets were used to amplify mouse actin cDNA using RT PCR:
5′ primer – 5′GTGGGCCGCTCTAGGCACCAA and 3′ primer –
5′CTCTTTCATCTCACGCACGATTTC.
Cell labeling
For measurements of cell surface area attachment, cells growing on
coverslips were washed with Hanks’ balanced salt solution (HBSS),
and 10 µM carboxyfluorescein diacetate succinimidyl ester (CFSE;
Molecular Probes, Eugene OR) in warm HBSS was added for 15
minutes at 37°C. Uptake of dye was stopped by washing cells twice
with HBSS. Cells were then re-fed and cultured overnight to allow
efflux of unbound CSFE but not CSFE covalently bound to
intracellular protein. The cells, still attached to the coverslips, were
fixed in 4% formaldehyde in CSK buffer (10 mM Pipes, pH 6.8, 300
mM sucrose, 100 mM NaCl, 3 mM MgCl2, 1 mM EGTA) and
mounted in ProLong (Molecular Probes). Surface area attachment was
determined from three to five fields each containing 15-20 cells; all
cells in a given field were measured. For cell volume measurements,
cells were labeled as described above, trypsinized, and live cells were
imaged. Images of fields were collected with a Zeiss Axioplan 2
fluorescence microscope with a CCD camera and computer
workstation running Metamorph version 3.5. Measurements were
made in Adobe Photoshop (version 6.0) using the magnetic lasso tool
to outline fluorescent cell areas and the histogram function to count
pixels in those areas, or using the line tool to measure cell diameters.
For statistical analysis of cell attachment area and volume
measurements, a non-parametric test (Mann-Whitney) was utilized
since the residuals were not normally distributed.
Papanicolau staining was performed as previously described
(Fischer et al., 1998b) in duplicate on cells grown to about 75%
confluency on glass coverslips, afterwards the cells were rinsed once
with PBS and then immediately fixed without air-drying in 95% Flex
alcohol (Richard-Allan Scientific, Kalamazoo, MI). Flex is a
proprietary mixture of ethanol, methanol and propanol with 5% water
widely used in clinical cytopathology laboratories as a fixative.
Blinded comparisons of cells with and without tetracycline induction
were performed by a board certified cytopathologist to see if
differences could be detected, as previously described (Fischer et al.,
1998b). To measure nuclear two-dimensional areas, cells were grown
to about 75% confluency on glass coverslips, rinsed with PBS,
immediately flooded with 95% Flex alcohol, stained for 15 minutes
in DAPI dissolved in absolute methanol at 1 µg/ml, rinsed three times
with Flex alcohol, and mounted with DAKO Fluorescent Mounting
Medium (Carpenteria, CA). No air-drying took place before or after
the DAPI staining. After threshholding to remove background
fluorescence, Image Tool Version 3.0 (University of Texas Health
Science Center, San Antonio, TX) was used to calculate the number
of fluorescent pixels per nucleus of the DAPI-stained cells. The effect
of dominant-negative BRG1 expression on nuclear areas was
evaluated by the Welch-Aspin t-test for unequal variances (Snedecor
and Cochran, 1989). The distributional characteristics of nuclear areas
were evaluated graphically by inspection of frequency histograms of
residuals and by the Kolmogorov-Smirnov goodness of fit test for
normality (Siegel, 1956) again on residuals. The residuals were
generated by subtracting group means from the observed areas.
Immunofluorescence staining for F-actin and paxillin was
performed as described previously (Wagner et al., 2003) on cells
grown on coverslips. Coverslips were fixed and permeabilized, then
incubated with monoclonal antibody against paxillin (BD
Pharmingen, San Diego, CA) at room temperature for 1 hour,
followed by incubation for 1 hour at room temperature with
rhodamine-conjugated goat anti-mouse IgG (Molecular Probes). For
Journal of Cell Science 117 (24)
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co-localization of F-actin with paxillin, FITC-phalloidin (Molecular
Probes) at 10 µg/ml was added along with the secondary antibody.
Matrigel invasion assay
The invasion assay was performed as recommended by the
manufacturer (BD Biosciences, cat. no. 354481, Bedford, MA). In
short, B05-1 cells were grown for 3 days with or without tetracycline.
After 3 days, cells were resuspended in medium containing or lacking
tetracycline and seeded at a density of 1.25×105 cells per well
containing a Matrigel insert. Invasion chambers were incubated in a
humidified tissue culture incubator, at 37°C, 5% CO2 atmosphere.
After 22 hours, chambers were removed; the cells that had not invaded
were swabbed with cotton and washed away, and the invading cells
were fixed in 4% formaldehyde and stained with 1% Toluidine for 2
minutes. The cells were scored using a Zeiss microscope at 40×
magnification. Fields were chosen in the center of the membrane as
well as in the periphery of the membrane for true representation of
the cell number throughout the membrane. The data on cell invasions
is from duplicates of two independent experiments; 502 cells were
counted in total. Results were analyzed by a Mann-Whitney non-
parametric test.
Results
We previously described NIH3T3-derived cell lines that are
tetracycline regulated to inducibly express ATPase deficient,
non-functional alleles of BRG1, the ATPase that forms the
catalytic core of some SWI/SNF chromatin remodeling
enzymes (de la Serna et al., 2000). B22, B24 and B05-1 cells
express ATPase-deficient BRG1 upon removal of tetracycline,
while tet-VP16 cells inducibly express only the tet-VP16 trans-
activator and therefore serve as a control cell line (de la Serna
et al., 2000). Expression of ATPase-deficient BRG1 inhibits the
ability of these cells to activate the hsp70 gene in response to
some cellular stresses (de la Serna et al., 2000), and prevents
prohibitin-mediated repression of E2F-induced transcription
(Wang et al., 2002). Expression of ATPase-deficient BRG1
inhibits the ability of cells to activate tissue-specific gene
expression and to trans-differentiate into muscle cells upon
introduction of MyoD or related muscle regulatory factors (de
la Serna et al., 2001a; de la Serna et al., 2001b; Roy et al.,
2002). Similarly, activation of adipocyte-specific markers and
trans-differentiation into adipocytes upon introduction of
PPARγ, C/EBPα or C/EBPβ is blocked by expression of
dominant negative BRG1 (Salma et al., 2004). Thus the mutant
BRG1 allele functions as a dominant negative with regard to
these gene regulation events, however, the expression of some
inducible loci as well as several constitutively expressed genes
is unaffected by the mutant enzyme (de la Serna et al., 2000;
Hill et al., 2004).
We noted that when equivalent numbers of cells were plated
in the presence or absence of tetracycline, the cells expressing
mutant BRG1 became confluent faster (Fig. 1a). This
observation was most obvious for the B05-1 line, which
consistently produced the highest level of mutant BRG1
expression among the cell lines isolated. We expected that
these cells were dividing at a faster rate after expression of the
mutant allele, but by manual counting of the B05-1 cells shown
in Fig. 1a we found that there were 609 cells in the sample
grown in the presence of tetracycline and 600 cells in the
sample grown without tetracycline. Moreover, cell counts for
3 days after removal of tetracycline showed no effect on the
rate of cell division (Fig. 1b). FACS analysis confirmed these
results (data not shown), however, in some experiments where
the cells were lightly trypsinized before fixation, side scatter
profiles suggested that cells expressing the mutant BRG1 were
larger than those not expressing the mutant allele (data not
shown).
To better examine cell size and shape, we grew cells on
coverslips in the presence or absence of tetracycline for 3 days.
Proteins were fluorescently tagged in living cells with
carboxyfluorescein diacetate succinimidyl ester (CFSE)
(Fujioka et al., 1994; Lyons and Parish, 1994). Fluorescent
images were collected and the area of the attachment surface
between the cell and the coverslip was measured using Adobe
Photoshop (Fig. 2a; see Materials and Methods). No difference
in attachment area was observed for the control tet-VP16 cells
in the presence or absence of tetracycline (Table 1). The mean
Fig. 1. Changes in cell physical appearance but not in the rate of cell
division upon expression of mutant BRG1. (a) Cells expressing
mutant BRG1 (–tet) change appearance and reach confluence faster
than control cells (+tet). (b) Cell counts for each cell line grown in
the presence or absence of tetracycline for 3 days.
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cell attachment area of B05-1 cells expressing mutant BRG1
(n=61) was 2.96 times larger than that of control B05-1 (Table
1: n=65; P<10–19 by Mann-Whitney non-parametric test). The
distribution of attachment areas for individual B05-1 cells is
presented in Fig. 2b.
Subsequently, we obtained images of similarly stained,
trypsinized cells, measured cell diameters and calculated the
approximate cell volume using the formula for volume of a
sphere. The data indicated a 1.69-fold increase in total cell
volume for B05-1 cells expressing mutant BRG1 (n=56)
relative to control B05-1 cells (Table 1: n=60; P<5×10–12 by
Mann-Whitney non-parametric test) and no difference for the
tet-VP16 cells grown in the absence or presence of tetracycline
(Table 1). The distribution of cell volumes for individual B05-
1 cells is presented in Fig. 2c.
To examine nuclear size in these cells, we stained cells with
DAPI, collected digital images, and measured the nuclear two-
dimensional area. Average surface area of the nuclei of cells
grown in the presence of tetracycline (n=239) was 198±58 µm2
and of those grown in the absence of tetracycline (n=158) was
228±51 µm2. Thus, the nuclear area of cells expressing mutant
BRG1 was about 10% larger (Table 1; P<10–7 by Welch-Aspin
t-test). Detailed examination of heterochromatin staining in
Papanicolau-stained cells indicated no differences in large-
scale heterochromatin organization due to the expression of
mutant BRG1 (Fig. 2d,e) such as has been noted for oncogene-
transformed cells (Fischer et al., 1998a; Fischer et al., 1998b).
No changes in nucleolar features or in either the basophilia or
texture of the cytoplasm were observed. Thus, expression of
the mutant BRG1-based SWI/SNF enzymes induced a change
in the size of both the cells and the nuclei but did not grossly
alter heterochromatin organization or other cytological
features.
Given the change in cell size and shape observed in the B05-
1 cells, we examined focal adhesions to determine whether
they differed in the larger cells. Paxillin is recruited to focal
adhesions upon interaction with integrins and is localized at
the end of actin stress fibers. Fluorescent images of B05-1 cells
doubly stained with phalloidin and an antibody against paxillin
revealed that paxillin-containing structures were more
numerous, more elongated, and stained more intensely in the
larger cells expressing the mutant BRG1 allele (Fig. 3a-b).
Nuclear staining was observed with the paxillin antibody; it has
been reported that paxillin shuttles between the nucleus and
cytoplasm in NIH3T3 cells (Woods et al., 2002). Nuclei
staining by both the paxillin antibody and DAPI (Fig. 3g-h)
also confirmed that the expression of mutant BRG1 increased
nuclear size. The pattern of actin stress fiber staining was
largely unchanged (Fig. 3c-d), and western analysis showed
that cellular levels of actin and paxillin protein were similar for
each cell line irrespective of growth conditions (Fig. 3i). Thus
the change in cell attachment area correlates with a change in
Journal of Cell Science 117 (24)
Fig. 2. Mutant BRG1 causes an increase in the size of the cell and
the nucleus. (a) Image of a CSFE-labeled cell (left) and the
corresponding DIC image (right). Bar, 10 µm. (b) Distribution of cell
surface attachment area (in µm2) for B05-1 cells grown in the
presence (n=65) or absence (n=61) of tetracycline for 3 days. Cells
were at 20-25% confluence to permit examination of individual cells.
(c) Distribution of cell volume in (in µm3) for B05-1 cells grown to
20-25% confluence in the presence (n=60) or absence (n=56) of
tetracycline for 3 days. (d,e) B05-1 cells grown in the presence (d) or
(e) absence of tetracycline for 3 days were Papanicolaou stained to
examine the appearance and size of the nucleus. Bar, 10 µm.
Table 1. Effects of mutant BRG1 expression on cell and nuclear size
Tet-VP16 + tetracycline Tet-VP16 – tetracycline
n Mean s.d. n Mean s.d. P*
Cell area µm2 43 937 452 31 998 488 NS
Cell vol. µm3 18 2323 1262 18 2136 1379 NS
Nuc. area µm2 ND ND
B05-1 + tetracycline B05-1 – tetracycline
n Mean s.d. n Mean s.d. P*
Cell area µm2 65 703 307 61 2078 800 <10E-19
Cell vol. µm3 60 2273 227 56 3853 441 <10E-11
Nuc. area µm2 239 198 58 158 228 51 <10E-7
ND, not determined; NS, not significant.
*See Materials and Methods and text for statistical analysis.
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focal adhesion structure and distribution but not with changes
in levels of paxillin.
We next asked whether the larger cells had increased levels
of proteins involved in cell adhesion. Surprisingly, we observed
that protein levels for the urokinase-type plasminogen activator
receptor (uPAR) were greatly increased in the cells expressing
mutant BRG1 (Fig. 4a). uPAR binds urokinase, a serine
protease that affects multiple components of the extracellular
matrix (Wang, 2001). uPAR levels are activated upon drug-
induced disruption of the actin or tubulin cytoskeleton
(Bayraktutan and Jones, 1995), and uPAR is frequently
overexpressed in metastatic tumors. Additionally, uPAR binds
to vitronectin and several members of the integrin family,
underscoring a role for uPAR in cell adhesion (Wei et al., 1996;
Yebra et al., 1996). We therefore examined the levels of several
integrins, as well as other attachment proteins. αV and α5
integrins were modestly overexpressed in cell lines after
expression of mutant BRG1 (Fig. 4b). No change in expression
levels was observed for β1 integrin, N-cadherin, β-catenin, or
focal adhesion kinase (data not shown).
Since uPAR overexpression is associated with metastases,
we addressed whether the cells expressing dominant negative
BRG1 also might express elevated levels of proteins associated
with extracellular matrix invasion. As a functional readout, we
utilized a Matrigel invasion assay. B05-1 cells grown in the
presence or absence of tetracycline were seeded onto Matrigel-
containing chambers and the number of invading cells was
determined. Cells expressing dominant negative BRG1 did not
show increased invasiveness; in fact, a twofold decrease was
observed (Fig. 5). We conclude that the elevated levels of
proteins known to be involved in cell adhesion do not correlate
with an increase in extracellular matrix invasive properties.
Since the levels of uPAR protein were misregulated in cells
expressing dominant negative BRG1, we sought to determine
Fig. 3. Expression of mutant BRG1 causes a change in the size and
distribution of focal adhesions but not in paxillin or actin protein
levels. Immunostaining for (a,b) paxillin, (c,d) phalloidin, (e,f) the
merged images of a,c and b,d, respectively, and (g,h) DAPI staining
in B05-1 cells grown to approximately 50% confluence in the
presence (a,c,e,g) or absence (b,d,f,h) of tetracycline for 3 days. Bar,
10 µm. (i) Western blot demonstrates that total cellular paxillin and
actin levels are unchanged by tetracycline or expression of mutant
BRG1 in three different cell lines. Flag immunoreactivity
demonstrates that the mutant BRG1 was expressed.
Fig. 4. Cells expressing mutant BRG1 show increased levels of some
adhesion proteins. Western blots against urokinase receptor (a) and
αV and α5 integrins (b) indicate increased levels in each of the three
cell lines expressing mutant BRG1. Phosphatidylinositol 3-kinase
(PI3K) levels were monitored as a loading control; Flag levels
indicate the level of mutant BRG1 protein expressed in each line.
The tet-VP16 samples probed for uPAR levels were run on a separate
gel and spliced into the figure.
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whether this was a direct consequence of inhibition of uPAR
transcription. Northern blot analysis revealed that levels of
uPAR mRNA were not significantly affected by the presence
of dominant negative BRG1 (Fig. 6). We conclude that the
misregulation of uPAR levels in cells expressing dominant
BRG1 occurs via an indirect mechanism.
Discussion
Changes in cell size and shape have been correlated with
changes in cellular proliferation and gene expression.
However, most studies seeking to alter cell size and shape have
done so via manipulation of the attachment surface. Here, we
present evidence that expression of a mutant chromatin
remodeling enzyme, which previously has been documented to
act as an inhibitor of several gene activation events, results in
an increase in cell size and attachment area that correlates with
over-expression of several proteins involved in cell adhesion.
To our knowledge, this system for manipulating cell size and
shape is novel in that it occurs via manipulation of a specific
protein, without the induction of cellular differentiation or
transformation or arrest of the cell cycle, and without alteration
of the composition or size of the cell attachment surface.
Previous work has demonstrated that re-introduction of
BRG1 into the BRG1- and hBRM-deficient, human adrenal
adenocarcinoma tumor line, SW13, induces cell cycle arrest
and the formation of cells that are larger and flatter than
untransfected cells (Asp et al., 2002; Dunaief et al., 1994;
Shanahan et al., 1999; Strober et al., 1996). This phenotype
was shown to be dependent on the retinoblastoma (RB) tumor
suppressor, as BRG1 physically interacted with RB and use of
an RB-binding deficient BRG1 allele significantly attenuated
the phenotype (Dunaief et al., 1994). Further work
demonstrated similar findings for the related hBRM protein,
though multiple hBRM mutants, including the ATPase-
deficient mutants, caused similar attenuation of the growth-
arrested, flat cell phenotype (Strober et al., 1996). Thus, in
these experiments, the presence of BRG1, not the absence of
Brg1 function, induced cell cycle arrest. The interpretation put
forth was that BRG1 and hBRM were demonstrating tumor
suppressor activity because of the induced cell cycle arrest. The
mechanism resulting in the induction of growth arrest and the
flat cell phenotype upon re-introduction of BRG1/hBRM
remains undetermined.
However, it has long been appreciated that cell growth
continues when cell division is blocked (Johnston et al., 1977).
Thus it is possible, if not likely, that transient re-introduction
of BRG1 or hBRM under the control of a heterologous
promoter resulted in relatively high levels of BRG1 or hBRM
that induced cell cycle arrest. The resulting increase in cell size
under such conditions is probably a continuation of metabolic
pathways controlling cell growth that only cease when cell
division fails. Recent studies have shown that cell growth,
even in the absence of cell division, can be affected by
mammalian TOR protein, a highly conserved member of the
phosphatidylinositol kinase family (Fingar et al., 2002). This
situation clearly differs from the observations we have made.
In our cells, a lack of Brg1 function induces changes in cell
size and shape without apparently affecting cell cycle, strongly
suggesting that different molecular mechanisms are involved.
Recently, two other groups have reported alterations in cell
morphology in response to re-introducing SWI/SNF subunits
into tumor cell lines deficient for that specific subunit. Asp et
al. succeeded in isolating SW13 clones stably transfected with
BRG1 that could continue to divide for a finite number of
divisions (Asp et al., 2002). These clones also exhibited flat
cell morphology, consistent with the previous studies described
above. SW13 clones expressing ATPase-deficient BRG1 could
be propagated without inducing cell cycle arrest. These authors
noted that the BRG1-expressing SW13 cells formed thick actin
filaments that resembled stress fibers in the cell body, whereas
SW13 cells and SW13 cells expressing ATPase-deficient
BRG1 did not have such structures and showed only thin actin
filaments that were abundant at the cell periphery. In contrast,
the changes in cell size and shape that we observed were not
accompanied by changes in the filamentous actin structure in
our cells (Fig. 3i). Again, this suggests that the changes in cell
structure observed upon re-introduction of BRG1 in SW13
cells differs from the mechanisms by which BRG1 affects cell
size and shape in proliferating fibroblastic cell lines.
In addition, Medjkane and co-workers constructed cell lines
that inducibly expressed the hSNF5/INI1 subunit of the
SWI/SNF complex in hSNF5/INI1-deficient tumor cells
(Medjkane et al., 2004). Upon re-expression of hSNF5/INI1,
the cells underwent cell cycle arrest and appeared more
rounded and smaller. This observation is consistent with our
results: hSNF5/INI1 deficient cells and cells expressing
dominant negative BRG1 are larger than their counterparts
expressing wild-type hSNF5/INI1 or BRG1. Moreover, these
authors observed a disappearance of paxillin-stained focal
Journal of Cell Science 117 (24)
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Fig. 5. Expression of ATPase-deficient BRG1 significantly reduces
the invasion of Matrigel membrane by B05-1 cells (P<0.05, by
Mann-Whitney non-parametric test). The average number of
invading cells is presented ±s.d.
Fig. 6. uPAR mRNA levels are not misregulated by dominant
negative BRG1. Northern blot analysis shows levels of uPAR and β-
actin mRNAs in two different lines (B05-1 and B22) that express
dominant negative BRG1 upon removal of tetracycline.
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adhesions upon expression of hSNF5/INI1. However, as with the
results of Asp and co-workers (Asp et al., 2002), these authors
observed changes in actin cytoskeleton structure, as restoration
of hSNF5/INI1 expression induced a loss of actin stress fibers.
The disparate findings regarding differences in actin cytoskeletal
staining may reflect cell-type-specific differences.
The absence of a grossly altered large-scale chromatin
organization when mutant SWI/SNF enzymes are expressed
suggests that SWI/SNF has a more focused role in chromatin
remodeling than other factors that cause large-scale changes in
heterochromatin organization. The observation that SWI/SNF
function is inhibited by the incorporation of linker histone into
chromatin templates further supports this idea (Hill and
Imbalzano, 2000; Horn et al., 2002). Moreover, recent
temporal analyses of inducible gene expression events in
mammalian cells indicates that SWI/SNF enzymes function in
promoter modification immediately preceding and concurrent
with transcription initiation (Agalioti et al., 2000; Salma et al.,
2004; Soutoglou and Talianidis, 2002). Collectively, these
observations suggest that SWI/SNF enzymes function to alter
the structure and accessibility of chromatin at the level of
individual genes, not at the level of global chromatin structure.
Throughout the eukaryotic kingdom, SWI/SNF enzymes
selectively affect gene expression, both positively and
negatively (Holstege et al., 1998; Liu et al., 2001; Sudarsanam
and Winston, 2000), though the basis for promoter selectivity
is not known. Thus, the fact that some, but clearly not all,
adhesion proteins are misregulated upon expression of mutant
BRG1-based SWI/SNF enzymes is in agreement with previous
results. Over-expression of adhesion proteins upon induction
of the mutant SWI/SNF enzymes suggests that the normal
function of the enzyme is to negatively regulate levels of these
proteins. However, the northern blot presented in Fig. 6
strongly suggests that, at least for the case of uPAR expression,
BRG1-containing SWI/SNF enzymes negatively affect gene
expression via an indirect mechanism. The pathway(s) through
which this is accomplished remain to be determined. Global
analysis of changes in gene expression due to the expression
of ATPase-deficient BRG1 may help to address this question.
Interestingly, mice heterozygous for BRG1 are susceptible
to tumor formation (Bultman et al., 2000), and BRG1 is absent
from a number of different tumor cells lines (DeCristofaro et
al., 2001; Wong et al., 2000). We hypothesize that the tumor
suppressor function of BRG1 may be related to its role in
regulating the levels of surface attachment molecules and the
interactions they make with their extracellular environment.
Misregulation of cell attachment properties may be one step by
which BRG1-deficient or mutant cells promote tumorigenesis.
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